Skip to main content

Advertisement

SpringerLink
Log in

A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Germline mutations in DNA repair-related genes have been recently reported in cases with familial non-medullary thyroid carcinoma (FNMTC). A Portuguese family from the Roma ethnic group with four members affected with papillary thyroid carcinoma (PTC), and three members with multinodular goiter (MNG) was identified. The aim of this study was to investigate the involvement of DNA repair-related genes in the etiology of FNMTC in this family and in the Roma ethnic group.

Methods

Ninety-four hereditary cancer predisposition genes were analyzed through next-generation sequencing. Sanger sequencing was used for variant confirmation and screening. Twelve polymorphic markers were genotyped for haplotype analysis in the CHEK2 locus.

Results

A germline pathogenic frameshift variant in the CHEK2 gene [c.596dupA, p.(Tyr199Ter)] was detected in homozygosity in the proband (PTC) and in his brother (MNG), being heterozygous in his mother (PTC), two sisters (PTC), and one nephew (MNG). This variant was absent in 100 general population controls. The screening of the CHEK2 variant was extended to other Roma individuals, being detected in 2/33 Roma patients with thyroid cancer, and in 1/15 Roma controls. Haplotype segregation analysis identified a common ancestral core haplotype (Hcac), covering 10 Mb in the CHEK2 locus, shared by affected CHEK2 variant carriers. Analysis of 62 individuals CHEK2 wild-type indicated that none presented the Hcac haplotype. The estimated age for this variant suggested that it was transmitted by a relatively recent common ancestor.

Conclusions

We identified a founder CHEK2 pathogenic variant, which is likely to underlie thyroid cancer and other cancer manifestations in the Roma population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Q.T. Nguyen, E.J. Lee, M.G. Huang, Y.I. Parkn, A. Khullar, R.A. Plodkowski,Diagnosis and treatment of patients with thyroid cancer. Am. Health Drug Benefits. 8(1), 30–40 (2015)

    PubMed  PubMed Central  Google Scholar 

  2. R.L. Siegel, K.D. Mille, A. Jemal, Cancer Statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017)

    Article  PubMed  Google Scholar 

  3. C. Sturgeon, O.H. Clark, Familial nonmedullary thyroid cancer. Thyroid 15(6), 588–593 (2005)

    Article  PubMed  Google Scholar 

  4. A.E. Pinto, G.L. Silva, R. Henrique, F.D. Menezes, M.R. Teixeira, V. Leite, B.M. Cavaco, Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. Eur. J. Endocrinol. 170, 321–327 (2014)

    Article  CAS  PubMed  Google Scholar 

  5. S.P. Yang, J. Ngeo, Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr. Relat. Cancer 23(12), R577–R595 (2016)

    Article  CAS  Google Scholar 

  6. J. Klubo-Gwiezdzinska, Y. Kushchayeva, S.K. Gara, E. Kebebew. Familial non-medullary thyroid cancer. In Practical Management of Thyroid Cancer, ed. by U.K. Mallick, C. Harmer (Springer, Cham, 2018), pp. 241–270

  7. J.A. Carney, C. Lyssikatos, R.R. Seethala, P. Lakatos, A. Perez-Atayde, H. Lahner et al. The spectrum of thyroid gland pathology in carney complex: the importance of Follicular Carcinoma. Am. J. Surg. Pathol. 42(5), 587–594 (2018)

    Article  PubMed  PubMed Central  Google Scholar 

  8. J. Dotto, V. Nosé, Familial thyroid carcinoma: a diagnostic algorithm. Adv. Anat. Pathol. 15(6), 332–349 (2008)

    Article  PubMed  Google Scholar 

  9. J.E. Hall, D.J. Abdollahian, R.J. Sinard, Thyroid disease associated with Cowden syndrome: a meta-analysis. Head Neck 35(8), 1189–1194 (2013)

    Article  PubMed  Google Scholar 

  10. C.D. Malchoff, D.M. Malchoff, The genetics of hereditary nonmedullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 87(6), 2455–2459 (2002)

    Article  CAS  PubMed  Google Scholar 

  11. C.D. Malchoff, M. Sarfarazi, B. Tendler, F. Forouhar, G. Whalen, V. Joshi et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J. Clin. Endocrinol. Metab. 85(5), 1758–1764 (2000)

    CAS  PubMed  Google Scholar 

  12. M. Rohaizak, A.Y. Jasmi, M.A.M. Ismail, M.J.J. Munchar, F.A. Meah, Thyroid carcinoma in patients with familial adenomatous polyposis. Asian J. Surg. 26(3), 183–185 (2003).

    Article  PubMed  Google Scholar 

  13. G.R. Bignell, F. Canzian, M. Shayeghi, M. Stark, Y.Y. Shugart, P. Biggs, J. Mangion, R. Hamoudi, J. Rosenblatt, P. Buu et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am. J. Hum. Genet. 61(5), 1123–1130 (1997)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. F. Canzian, P. Amati, H.R. Harach, J.L. Kraimps, F. Lesueur, J. Barbier et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am. J. Hum. Genet. 63(6), 1743–1748 (1998)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. J.D. McKay, F. Lesueur, L. Jonard, A. Pastore, J. Williamson, L. Hoffman et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am. J. Hum. Genet. 69(2), 440–446 (2001)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. B.M. Cavaco, P.F. Batista, L.G. Sobrinho, V. Leite, Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J. Clin. Endocrinol. Metab. 93(11), 4426–4430 (2008).

    Article  CAS  PubMed  Google Scholar 

  17. I. Suh, S. Filetti, M.R. Vriens, M.A. Guerrero, S. Tumino, M. Wong et al. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery. 146(6), 1073–1080 (2009)

    Article  PubMed  Google Scholar 

  18. H. He, R. Nagy, S. Liyanarachchi, H. Jiao, W. Li, S. Suster et al. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res. 69(2), 625–631 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. E.S.W. Ngan, B.H.H. Lang, T. Liu, C.K.Y. Shum, M.T. So, D.K.C. Lau et al. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J. Natl Cancer Inst. 101(3), 162–175 (2009)

    Article  CAS  PubMed  Google Scholar 

  20. T. Rio Frio, A. Bahubeshi, C. Kanellopoulou, N. Hamel, M. Niedziela, N. Sabbaghian et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 305(1), 68–77 (2011)

    Article  CAS  PubMed  Google Scholar 

  21. H. He, A. Bronisz, S. Liyanarachchi, R. Nagy, W. Li, Y. Huang et al. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J. Clin. Endocrinol. Metab. 98(5), 973–980 (2013)

    Article  Google Scholar 

  22. J.S. Pereira, J.G. da Silva, R.A. Tomaz, A.E. Pinto, M.J. Bugalho, V. Leite et al. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine 49(1), 204–214 (2015)

    Article  CAS  PubMed  Google Scholar 

  23. S.K. Gara, L. Jia, M.J. Merino, S.K. Agarwal, L. Zhang, M. Cam et al. Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N. Engl. J. Med. 373(5), 448–455 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. J. Tomsic, H. He, K. Akagi, S. Liyanarachchi, Q. Pan, B. Bertani et al. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci. Rep. 5(1), 1–13 (2015)

    Article  Google Scholar 

  25. C. Liu, Y. Yu, G. Yin, J. Zhang, W. Wen, X. Ruan et al. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer. Biochem. Biophys. Res. Commun. 482(4), 590–596 (2017)

    Article  CAS  PubMed  Google Scholar 

  26. F. Ye, H. Gao, L. Xiao, Z. Zuo, Y. Liu, Q. Zhao et al. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma. Int. J. Cancer 144(6), 1321–1330 (2018)

    Article  PubMed  CAS  Google Scholar 

  27. C. Diquigiovanni, C. Bergamini, C. Evangelisti, F. Isidori, A. Vettori, N. Tiso et al. Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer. Int. J. Cancer. 143(7), 1706–1719 (2018)

    Article  CAS  PubMed  Google Scholar 

  28. S. Fahiminiya, L. de Kock, W.D. Foulkes, Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375(11), 1054–1067 (2016)

    Article  CAS  Google Scholar 

  29. A. Srivastava, A. Kumar, S. Giangiobbe, E. Bonora, K. Hemminki, A. Försti et al. Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in MAPK/ERK and PI3K/AKT signaling pathways. Biomolecules 9(10), 605 (2019)

    Article  CAS  PubMed Central  Google Scholar 

  30. Y. Yu, L. Dong, D. Li, S. Chuai, Z. Wu, X. Zheng et al. Targeted DNA sequencing detects mutations related to susceptibility among familial non-medullary thyroid cancer. Sci. Rep. 5, 16129 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Y. Wang, S. Liyanarachchi, K.E. Miller, T.T. Nieminen, D.F. Comiskey Jr, W. Li, H. He, A. de la Chapelle et al. Identification of rare variants predisposing to thyroid cancer. Thyroid 29(7), 946–955 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Y. Zhao, T. Yu, L. Chen, D. Xie, F. Wang, L. Fu, C. Cheng, Y. Li, X. Zhu, G. Miao, A germline CHEK2 mutation in a family with papillary thyroid cancer. Thyroid. 30(6), 924–930 (2020)

    Article  CAS  PubMed  Google Scholar 

  33. S. Martins, F. Calafell, C. Gaspar, V.C. Wong, I. Silveira, G.A. Nicholson et al. Asian origin for the worldwide-spread mutational event in Machado-Joseph disease. Arch. Neurol. 64(10), 1502–1508 (2007)

    Article  PubMed  Google Scholar 

  34. J.H. Choi, R. Balasubramanian, P.H. Lee, N.D. Shaw, J.E. Hall, L. Plummer, R. Quinton, Expanding the spectrum of founder mutations causing isolated gonadotropin-releasing hormone deficiency. J. Clin. Endocrinol. Metab. 100(10), E1378–E1385 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. T. Strachan, A. Read. Human Molecular Genetics, 4th edn (Garland Science, Taylor & Francis Group, Madison Avenue, New York, 2010)

  36. P.M. Machado, R.D. Brandão, B.M. Cavaco, J. Eugénio, S. Bento, M. Nave, F. Vaz, Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J. Clin. Oncol. 25(15), 2027–2034 (2007)

    Article  CAS  PubMed  Google Scholar 

  37. M. Pinheiro, I. Francisco, C. Pinto, A. Peixoto, I. Veiga, B. Filipe, R. Santos, The nonsense mutation MSH2 c. 2152C> T shows a founder effect in Portuguese Lynch syndrome families. Genes, Chromosomes Cancer. 58(9), 657–664 (2019)

    CAS  PubMed  Google Scholar 

  38. S. Matsuoka, M. Huang, S.J. Elledge, Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282(5395), 1893–1897 (1998)

    Article  CAS  PubMed  Google Scholar 

  39. B.M. Cavaco, P.F. Batista, C. Martins, A. Banito, F. do Rosário, E. Limbert, L.G. Sobrinho, V. Leite, Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr. Relat. Cancer. 15(1), 207–215 (2008)

    Article  PubMed  Google Scholar 

  40. I.J. Marques, M.M. Moura, R. Cabrera, A.E. Pinto, J. Simões-Pereira, C. Santos, F.D. Menezes, D. Montezuma, R. Henrique, M. Rodrigues Teixeira, V. Leite, B.M. Cavaco, Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas. Clin. Endocrinol. 87(4), 394–399 (2017)

    Article  CAS  Google Scholar 

  41. M. Fiore, X. Pillois, P. Nurden, A.T. Nurden, F. Austerlitz, Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur. J. Hum. Genet. 19(9), 981–987 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  42. M. Cabral, A.V. Neves. Caracterização das condições de habitação das Comunidades Ciganas residentes em Portugal (Instituto da Habitação e da Reabilitação Urbana, I.P, Lisboa, 2014) pp. 1–28

  43. C. Cybulski, B. Górski, T. Huzarski, B. Masojć, M. Mierzejewski, T. Dębniak et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75(6), 1131–1135 (2004)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. C. Stanislaw, Y. Xue, W.R. Wilcox, Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol. Med. 13(1), 55–67 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. R. Vassilopoulou-Sellin, L. Palmer, S. Taylor, C.S. Cooksley, Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 85(3), 696–705 (1999)

    Article  CAS  PubMed  Google Scholar 

  46. A.Y. Chen, L. Levy, H. Goepfert, B.W. Brown, M.R. Spitz, R. Vassilopoulou-Sellin, The development of breast carcinoma in women with thyroid carcinoma. Cancer. 92(2), 225–231 (2001)

    Article  CAS  PubMed  Google Scholar 

  47. C.I. Li, M.A. Rossing, L.F. Voigt, J.R. Daling, Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control. 11(9), 805–811 (2000)

    Article  CAS  PubMed  Google Scholar 

  48. M. Siołek, C. Cybulski, D. Gąsior-Perczak, A. Kowalik, B. Kozak-Klonowska, A. Kowalska et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int. J. Cancer. 137(3), 548–552 (2015)

    Article  PubMed  CAS  Google Scholar 

  49. M.A. Adank, M.A. Jonker, I. Kluijt, S.E. van Mil, R.A. Oldenburg, W.J. Mooi, A.W. van der Vaart, CHEK2* 1100delC homozygosity is associated with a high breast cancer risk in women. J. Med. Genet. 48(12), 860–863 (2011)

    Article  CAS  PubMed  Google Scholar 

  50. M. Kaczmarek-Ryś, K. Ziemnicka, S.T. Hryhorowicz, K. Górczak, J. Hoppe-Gołębiewska, M. Skrzypczak-Zielińska, I. Siatkowski, The c. 470T>C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hered Cancer Clin. Pract. 13(1), 8 (2015)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. P. Apostolou, F. Fostira, V. Mollaki, A. Delimitsou, M. Vlassi, G. Pentheroudakis, I. Konstantopoulou, Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. J. Hum. Genet. 63(8), 877–886 (2018)

    Article  CAS  PubMed  Google Scholar 

  52. E. Złowocka, C. Cybulski, B. Górski, T. Dębniak, M. Słojewski, D. Wokołorczyk, R.J. Scott, Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int. J. Cancer. 122(3), 583–586 (2008)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the patients and their families for their cooperation.

Funding

This work was funded by Liga Portuguesa Contra o Cancro — Núcleo Regional do Sul (LPCC-NRS), Televisão Independente (TVI), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), iNOVA4Health — UIDB/04462/2020 (a program financially supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência), and Associação de Endocrinologia Oncológica.

Author information

Authors and Affiliations

  1. Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

    Carolina Pires, Inês Jorge Marques, Ana Saramago & Branca Maria Cavaco

  2. Chronic Diseases Research Centre (CEDOC), Universidade Nova de Lisboa, Lisboa, Portugal

    Inês Jorge Marques

  3. Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal

    Inês Jorge Marques

  4. Serviço de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

    Daniela Dias & Valeriano Leite

Authors
  1. Carolina Pires
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inês Jorge Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Saramago
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valeriano Leite
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Branca Maria Cavaco
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.P.: investigation, methodology, formal analysis, data analysis, writing—original draft, writing—review and editing; I.J.M.: investigation, methodology, formal analysis, data analysis, writing—review and editing; D.D.: investigation, clinical data analysis, writing—review and editing; A.S.: methodology, data analysis, writing—review and editing; V.L.: investigation, clinical data analysis, writing—review and editing; B.M.C.: investigation, conceptualization, supervision, formal analysis, data analysis, funding acquisition, writing—review and editing.

Corresponding author

Correspondence to Branca Maria Cavaco.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval

This study was approved by the Ethical Committee of Instituto Português de Oncologia de Lisboa Francisco Gentil, and is in accordance with the ethical standards from the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

The collection of biological samples from all subjects involved in this study was performed after written informed consent.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pires, C., Marques, I.J., Dias, D. et al. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer. Endocrine 73, 588–597 (2021). https://doi.org/10.1007/s12020-021-02660-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-021-02660-x

Keywords

Search

Navigation